ArticleInflammatory intestinal diseases2020

A Multicentre, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of the S1P Receptor Agonist KRP203 in Patients with Moderately Active Refractory Ulcerative Colitis.

Heinfried H Radeke et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.